This stent is the company's second balloon-expandable stent for the treatment of intracranial ischemic stenosis, a narrowing of the blood vessels of the brain that has the potential to cause stroke.
The investigational device exemption study the company is conducting is designed to compare outcomes between patients treated with the stent and another medical therapy, Micrus said.
The biotechnology company's shares closed at $14.96 on Friday. Christie Rizk cr/tk1
COPYRIGHT
Copyright Thomson Financial News Limited 2007. All rights reserved. The copying, republication or redistribution of Thomson Financial News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Financial News.
MMMM

More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index